



**23 February 2022**

## **SAVE THE DATE: eTheRNA immunotherapies Webinar**

**Please join us for our upcoming Webinar on:**

**Wednesday, 2<sup>nd</sup> March 2022 from 10-11am ET | 3-4pm GMT | 4-5pm CET.**

eTheRNA's VP of Discovery [Stefaan De Koker, Ph.D.](#), will provide an overview of eTheRNA's mRNA-Lipid Nanoparticles (LNP) technology developed for its cancer immunotherapy programs.

This will be followed by a Q&A discussion with Principal Investigator [Michael J. Mitchell, Ph.D.](#), Professor in the Department of Bioengineering at the University of Pennsylvania. The [Mitchell Lab](#) performs research that lies at the interface of biomaterials science, drug delivery, and cellular and molecular bioengineering to fundamentally understand and therapeutically target biological barriers. Currently, they are researching the synthesis of novel biomaterials and nanoparticles for the delivery of nucleic acids (siRNA, miRNA, mRNA, CRISPR-Cas9).

The session will conclude with Q&A open to the attendees.

[To Join the Webinar Please Register Here](#)

### **About eTheRNA immunotherapies**

eTheRNA is an mRNA technology discovery and development company with a full platform of integrated capabilities including: mRNA construct design and optimization; proprietary lipid nanoparticle (LNP) formulations which have demonstrated organ-specific distribution preclinically; process development and manufacturing capabilities for mRNA drug substance (gram GMP scale); and proprietary LNP / final product formulation technologies, including a lyophilized thermostable formulation in advanced development. With a focus on immune modulation and T Cell stimulation, eTheRNA is pursuing internal development programs to validate its core technologies and enable strategic partnerships in a range of geographic markets and therapeutic areas. eTheRNA is backed by a global syndicate of leading investors and is headquartered in Belgium with offices in New York and Hong Kong. To learn more, visit [www.etherna.be](http://www.etherna.be).